Tamibarotene targets heparin-binding protein for attenuating lung injury in sepsis.

These findings demonstrated that tamibarotene lessens sepsis-induced lung injury, and the effect could be exerted by targeting HBP and thereby deregulating the NF-κB signaling pathway.